, Volume 29, Issue 1, p 133
Date: 15 Jan 2011

Significance of microsatellite instability (MSI) for colorectal cancer following adjuvant therapy with doxifluridine

This is an excerpt from the content

Letter to Editor

We read with interest the study by Kang and colleagues published in the recent issue of Medical Oncology [1]. They examined the usefulness of mcrosatellite instability (MSI) status as a predictive factor for stage II or III colorectal cancer (CRC) patients who received adjuvant doxifluridine therapy. MSI-H showed a favorable survival trend for overall survival and significant survival benefit for relapse-free survival. In a univariate analysis, the doxifluridine-treated patients with MSI-H showed improved relapse-free survival compared to those with low or stable MSI (MSI-L/S), however, in a multivariate analysis, MSI-H was not significantly associated with relapse-free survival. Therefore, they concluded that MSI-H patients with stage II or III CRC did not seem to benefit from doxifluridine adjuvant therapy. As the author stated, the predictive role of the MSI status remains unclear at the present time. We have previously demonstrated that adjuvant chemotherapy is effe